bluebird bio, Inc. (NASDAQ:BLUE) Director John Maraganore sold 18,868 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the completion of the transaction, the director now directly owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

bluebird bio, Inc. (NASDAQ BLUE) traded up 1.10% on Monday, reaching $133.05. 859,526 shares of the company were exchanged. The stock has a 50 day moving average of $106.30 and a 200 day moving average of $96.34. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $136.85. The firm’s market capitalization is $6.07 billion.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.59) EPS. Equities analysts anticipate that bluebird bio, Inc. will post ($6.84) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “bluebird bio, Inc. (BLUE) Director Sells $2,475,670.28 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/18/bluebird-bio-inc-blue-director-sells-2475670-28-in-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. raised its position in bluebird bio by 5.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,600 shares of the biotechnology company’s stock worth $378,000 after acquiring an additional 191 shares in the last quarter. Fairfield Bush & CO. bought a new stake in bluebird bio during the second quarter worth $210,000. Raymond James Financial Services Advisors Inc. bought a new stake in bluebird bio during the second quarter worth $211,000. The Manufacturers Life Insurance Company raised its position in bluebird bio by 0.5% during the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after acquiring an additional 151 shares in the last quarter. Finally, Alpine Global Management LLC bought a new stake in bluebird bio during the second quarter worth $410,000.

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company reiterated an “outperform” rating and issued a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Barclays PLC assumed coverage on shares of bluebird bio in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price for the company. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Wedbush reiterated an “outperform” rating and issued a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. Finally, BidaskClub upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $107.86.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.